Agent Capital
Dr. Orloff joins Agent Capital following his position as EVP and Global Head of R&D for Alexion, where his leadership in expanding the development pipeline from three to 30 programs supported the recent $39 billion acquisition of Alexion by AstraZeneca. Prior to Alexion, Dr. Orloff was Global Head of R&D and Chief Scientific Officer at Baxalta, and has also held executive leadership roles with Novelion, Baxter International, Merck Serono, Novartis and Merck Research Laboratories. Before entering the biopharmaceutical industry, he was a faculty member at the Yale University School of Medicine.
This person is not in any offices
Agent Capital
Agent Capital is a healthcare investment firm focused on novel technologies and therapeutics that address unmet patient need. Their investment areas of focus are new products and technologies for oncology, immunology, neurology and rare disease indications. They make direct equity investments across all stages of development and types of financing rounds.